Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
